Tempus AI, Bristol Myers Sign Multi-Year Oncology Data and AI Deals
Tempus AI will license oncological data to Bristol Myers Squibb and provide access to its Lens platform under a multi-year agreement.
Tempus AI has entered into a multi-year agreement with Bristol Myers Squibb to license oncology data and provide access to its artificial intelligence-powered platform. The agreement gives Bristol Myers access to Tempus’s Lens Platform, its agentic AI platform for…